Translating Metastasis Research into Incredible New Therapies


1% of cancer research papers focus on metastatic cancer Less than 5% of cancer funding goes towards tackling metastatic cancer The clinical success rate of cancer drugs has dropped to 3.4% 90% of cancer patients who die, do so from cancer metastasis

There’s no doubt about it. This is a huge area of need.

Tackling metastatic cancer represents the greatest opportunity to improve the lives of most cancer patients. And for the first time we now have the opportunity to pull together as an oncology community and make real progress for patients.

“The most exciting oncology meeting to happen in years”

Immuno-oncology/CAR-T • New metastatic models • A groundswell of translational anti-metastatic research • AI • The quest for new oncology targets • New insights in cancer cell metabolism • A declining clinical success rate • Fresh thinking around clinical trials • New early-diagnostic technologies • The emerging influence of the microbiome.

These are all drivers that are converging to open up incredible new therapeutic opportunities in tackling metastasis. And this meeting address each of these topics and more with a an unrivalled speaker line-up and in a friendly, welcoming environment conducive to deep learning and networking.

This is an event for the entire oncology community – pharma, researchers and clinicians – to move beyond basic research and focus on the development of new therapies that tackle cancer where it hits hardest.

Confirmed Speakers

J Carl Barrett.png

J. Carl Barrett
Global Lead Translational Medicine Oncology R&D

Bruce Zetter.png

Bruce Zetter
Professor of Cancer Biology
Harvard University

Bob Weinberg.png

Bob Weinberg
Daniel K. Ludwig Professor for Cancer Research

Bob Kerbel.png

Robert Kerbel
Senior Scientist, Biological Sciences, Odette Cancer Research Program
Sunnybrook Research Institute

Maria A.S Broggi
Exploratory Immuno-Oncology Investigator
Novartis Institutes for BioMedical Research

Shou-Ching Jaminet.png

Shou-Ching Jaminet
Founder and Head of Research
Angiex Inc.

Christopher Kloss
Scientist, CAR T Discovery and Platform Development
The Janssen Pharmaceutical Companies of Johnson & Johnson

Farshad Guirakhoo.png

Farshad Guirakhoo
Chief Scientific Officer
GeoVax, Inc.

Bruce Littlefield.png

Bruce Littlefield
Distinguished Scientist and Head, Translational Medicine

Thomas Seyfried.png

Thomas Seyfried
Boston College

Andrew P Mazar.png

Andrew P Mazar
Chief Scientific Officer
Monopar Therapeutics

Kin-Hoe Chow
Associate Director, Center for Patient Derived Models
Dana-Farber Cancer Institute

Why Attend?


Unlock New Therapeutic Avenues

Explore new targets, mechanisms and modalities.


Shape Your Strategy Using Experts

Learn from the world’s leading cancer researchers.


Improve Clinical Success

Optimize metastatic model use, discover new endpoints and trial paradigms.


Make New Connections

Network with experts from academia, healthcare and pharma.

Key Topics Include

Topic Banner 2.png
  • Translate metastasis research into the clinic. Understand which targets, mechanisms and therapeutic avenues hold the most promise.

  • Implement metastatic models. Uncover clinically-relevant findings from new and emerging models of metastatic disease, and improve modelling to tackle immune-oncology toxicity.

  • Stop metastasis earlier. Learn how and why, coupled with new methods to detect cancer, the potential to stop metastasis before it’s too later is increasing.

  • AI and metastasis. What if AI could help rethink the metastasis/resistance equation? Find out how.

  • Biomarkers and metastasis. Explore new methods to select drug candidates, new biomarkers for metastasis and which biomarkers are most likely to be meaningful for patients.

  • Dormancy. Discover the most therapeutically relevant advances in our understanding of dormancy in metastasis.

Topic Banner 1.png
  • Immuno-oncology and metastasis. As metastasis research and CAR-T therapies converge, understand how new CAR-T cells are being generated for the eradication of advanced cancers.

  • Cancer as a metabolic disease. Learn about the prospects for metabolic therapies, including the most likely targets and pathways.

  • Overcoming anti-metastatic bottlenecks. Discuss how to overcome the barriers and bottlenecks to drive the development of therapies that tackle metastasis.

  • The microbiome and metastasis. Uncover the impact of microorganisms in carcinogenesis, cancer progression and metastasis, and the therapeutic implications of recent findings.

  • Endpoints and clinical trials. Define the relationship between established and novel tumor-based endpoints with overall survival rates in patients treated with immunotherapy, and discover/discuss new trial paradigms and endpoints.

  • Leverage data-driven approaches. Streamline big data research into clinically actionable interventions for the treatment of metastatic disease.